Covance Purchases Equity Stake in Caprion ...(rbor provisions of the Private Securitie...)

Date:12/16/2008

rbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.

'/>"/>

SOURCE Covance Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
2. Covance Decides to Pursue Its Original Preclinical Strategy in China
3. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
4. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
5. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
7. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
9. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
10. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes